Phase I First-in-Human Dose Escalation Study of the oral Casein Kinase 1α and Cyclin Dependent Kinase 7/9 inhibitor BTX-A51 in advanced MDS and AML.
Journal
Research square
ISSN: 2693-5015
Titre abrégé: Res Sq
Pays: United States
ID NLM: 101768035
Informations de publication
Date de publication:
15 Oct 2024
15 Oct 2024
Historique:
medline:
1
11
2024
pubmed:
1
11
2024
entrez:
1
11
2024
Statut:
epublish
Résumé
BTX-A51, a first-in-class oral small molecule inhibitor of casein kinase 1α (CK1α) and cyclin dependent kinase (CDK) 7 and 9, induces apoptosis of leukemic cells by activating p53 and inhibiting expression of
Identifiants
pubmed: 39483885
doi: 10.21203/rs.3.rs-4954060/v1
pmc: PMC11527261
pii:
doi:
Types de publication
Journal Article
Preprint
Langues
eng